Literature DB >> 29797073

[A young patient with full visual acuity, small visual field defects, and normal fluorescence angiogram].

S Serafini1, C P Lohmann2, M Ulbig2.   

Abstract

A 28-year-old female patient came to our clinic complaining of small central visual field defects in both eyes, without any impairments of visual acuity. She reported recent flu-like symptoms and work-related stress associated with high caffeine intake. Dark reddish cloverleaf-shaped lesions were noted in the macular region with red-free fundoscopy, and alterations of the external retinal layers were observed in spectral domain optical coherence tomography (SD-OCT). The visual field test (Octopus, program 32) revealed small central scotoma on both eyes. The fluorescein angiograms were normal. A suspected diagnosis of acute macular neuroretinopathy (AMNR) was made and the patient was scheduled for follow-up 4 weeks later. The follow-up examination showed persisting central scotoma as well as persistence of the lesions in the external retinal layers in OCT. The best-corrected visual acuity was still 20/20. In OCT angiography (OCT-A), a reduced correlation signal and therefore perfusion was detected in the outer retinal capillary plexus within the area of the fundoscopic macular lesions. Multimodal imaging, including SD-OCT and A‑OCT, plays a pivotal role in the diagnosis of acute macular neuroretinopathy. Even though no serious impairments of visual acuity are reported, patients should be informed about the possibility of permanent central scotoma.

Entities:  

Keywords:  AMNR; Acute macular neuroretinopathy; Multimodal imaging; OCT-A; SD-OCT

Mesh:

Year:  2019        PMID: 29797073     DOI: 10.1007/s00347-018-0733-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  1 in total

Review 1.  Optical coherence tomography angiography-derived flow density: a review of the influencing factors.

Authors:  Viktoria C Brücher; Jens J Storp; Nicole Eter; Maged Alnawaiseh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-09       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.